Vaccines were prepared in sterile, endotoxin-free (<0.05 EU/mL)
PBS (Gibco). For mice, vaccines were administered either subcutaneously in a
volume of 50 μL in each hind footpad or intravenously via the tail vein
in a volume of 200 μL. Adjuvants were either prepared in-house as
previously described33 (link) and
summarized in theSupplementary Materials and Methods or were acquired from commercial
sources: polyIC (InvivoGen, San Diego, CA), anti-CD40 agonist (clone FGK4.5,
BioXCell cat #BE0016–2, West Lebanon, NH), and CpG 1826 (InvivoGen).
polyICLC (Hiltonol) was a kind gift of A. M. Salazar (Oncovir). Animals treated
with checkpoint inhibitor (CPI), anti-PD-L1 (clone 10F.9G2, BioXCell cat
#BE0101), received 200 μg administered by the IP route in 100 μL
PBS. For NHP, SNP-7/8a was formulated in 1 mL PBS for each of 4 SC sites (left
and right deltoid; left and right thigh). Immunizations and blood sampling
occurred with the NHP under anesthesia (10 mg per kg weight ketamine HCl).
PBS (Gibco). For mice, vaccines were administered either subcutaneously in a
volume of 50 μL in each hind footpad or intravenously via the tail vein
in a volume of 200 μL. Adjuvants were either prepared in-house as
previously described33 (link) and
summarized in the
sources: polyIC (InvivoGen, San Diego, CA), anti-CD40 agonist (clone FGK4.5,
BioXCell cat #BE0016–2, West Lebanon, NH), and CpG 1826 (InvivoGen).
polyICLC (Hiltonol) was a kind gift of A. M. Salazar (Oncovir). Animals treated
with checkpoint inhibitor (CPI), anti-PD-L1 (clone 10F.9G2, BioXCell cat
#BE0101), received 200 μg administered by the IP route in 100 μL
PBS. For NHP, SNP-7/8a was formulated in 1 mL PBS for each of 4 SC sites (left
and right deltoid; left and right thigh). Immunizations and blood sampling
occurred with the NHP under anesthesia (10 mg per kg weight ketamine HCl).
